Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2024-01-17 00:00:00 ET · period of report 2024-01-12 · accession 0001968202-24-000034 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-01-17 | 2024-01-12 | REGN | Landry Robert E | EVP Fin CFO | M - OptEx | $378.98 | +800 | 23.4K | +4% | +$303.2K |
| D | 2024-01-17 | 2024-01-12 | REGN | Landry Robert E | EVP Fin CFO | F - Tax | $928.18 | -568 | 22.8K | -2% | -$527.2K |
| D | 2024-01-17 | 2024-01-12 | REGN | Landry Robert E | EVP Fin CFO | M - OptEx | $0.00 | -800 | 14.7K | -5% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-12 | M | A | 800 | $378.98 | 23,406 | D | — | — | |
| 2 | Common | Common Stock | 2024-01-12 | F | D | 568 | $928.18 | 22,838 | D | — | — | |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2024-01-12 | M | D | 800 | $0.00 | 14,687 | D | $378.98 · — to 2027-12-12 | 800 Common Stock | (F1) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |